Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Clinical Response Evaluation Toward Individualizing the Starting Dose of Dasatinib in Asian Patients with Chronic Myeloid Leukemia

Hyejin Shin, Jung-Eun Ha, Dae Young Zang, MDPhD, Sung-Hyun Kim, MD PhD, Young Rok Do, PhDMD, Won Sik Lee, MD PhD, Soo-Hyun Kim, Kyung-Mi Kee, Seon-Young Yang, So-Yoon Hwang, Eun-Jung Jang, Jangik Lee, PharmD, Dong-Wook Kim, MD

Blood (2020) 136 (Supplement 1): 6.

https://doi.org/10.1182/blood-2020-140626

Published: 2020

Journal Articles

Second Imatinib Discontinuation Outcomes in Patients Regaining Durable Deep Molecular Response in the Korean Imatinib Discontinuation Study; KID Study

Sung-Eun Lee, MD PhD, Joon Seong Park, MD, Young Rok Do, PhDMD, Sung-Hyun Kim, MD PhD, Dae Young Zang, MDPhD, Sukjoong Oh, MDPhD, Jae-Yong Kwak, Jeong-A Kim, Yeung-Chul Mun, MD, Won Sik Lee, MD PhD, Dong-Wook Kim, MD

Blood (2020) 136 (Supplement 1): 51–52.

https://doi.org/10.1182/blood-2020-139253

Published: 2020

Journal Articles

Current Treatment Patterns and Outcomes in Patients with Peripheral T-Cell Lymphoma: Updated Results of the Nationwide, Multi-Center Prospective Registry Study (CISL 1404)

Blood (2019) 134 (Supplement_1): 2844.

https://doi.org/10.1182/blood-2019-129664

Published: 2019

Journal Articles

Open-Labeled, Multicenter Phase II Study of Bortezomib for Maintenance Therapy in Patients with High Risk Diffuse Large B Cell Lymphoma (DLBCL): Borma Trial from Consortium for Improving Survival of Lymphoma (CISL)

Jae-Cheol Jo, MD, Ho Sup Lee, MD, Cheolwon Suh, Hye Jin Kang, MD PhD, Won Seog Kim, MD PhD, HyeonSeok Eom, MD PhD, Inho Kim, MD PhD, Ho-Jin Shin, MD PhD, Yong Park, Won Sik Lee, MD PhD, Young Rok Do, PhDMD, Lee Gyeong-Won, Sung Yong Oh, Sung-Nam Lim, MD, Seong Yoon Lee, MD

Blood (2019) 134 (Supplement_1): 2884.

https://doi.org/10.1182/blood-2019-132192

Published: 2019

Journal Articles

Prognostic Significance of Interim PET/CT Assessment for the Treatment of Advanced Stage of Marginal Zone Lymphoma in the Post Immunochemotherapy Era

Ga-Young Song, Seok Jin Kim, MD PhD, Sang Eun Yoon, Jin Seok Kim, MD PhD, Ho-Young Yhim, MD PhD, Youngil Koh, MD PhD, Sung Yong Oh, MD PhD, Ho Sup Lee, MD PhD, Ho-Jin Shin, MD PhD, Young Rok Do, MD PhD, Won Sik Lee, MD PhD, Lee Gyeong-Won, Dae Sik Kim, Yong Park, Deok-Hwan Yang, MD PhD

Blood (2019) 134 (Supplement_1): 4002.

https://doi.org/10.1182/blood-2019-126574

Published: 2019

Journal Articles

Results of Intercontinental Cooperative Non-Hodgkin T-Cell Lymphoma Prospective Registry Study

Blood (2019) 134 (Supplement_1): 4035.

https://doi.org/10.1182/blood-2019-126637

Published: 2019

Journal Articles

Long-Term Outcomes of Chronic Myeloid Leukemia Patients Who Lost Undetectable Molecular Residual Disease (UMRD) after Imatinib Discontinuation: Korean Imatinib Discontinuation Study (KIDS)

Sung-Eun Lee, MD, Joon Seong Park, MD, Hyeoung-Joon Kim, MD PhD, Sung-Hyun Kim, MD PhD, Dae Young Zang, MD PhD, Sukjoong Oh, MD PhD, Young Rok Do, PhDMD, Yunsuk Choi, MD, Jae-Yong Kwak, MD PhD, Jeong-A Kim, MD PhD, Kyoo Hyung Lee, MD PhD, Yeung-Chul Mun, MD, Won Sik Lee, MD PhD, Myung Hee Chang, MD, Jinny Park, MD PhD, Jihyun Kwon, MD, Dong-Wook Kim

Blood (2019) 134 (Supplement_1): 1643.

https://doi.org/10.1182/blood-2019-126376

Published: 2019

Journal Articles

High Incidence of Hepatitis B Viral Reactivation in Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors

Jieun Uhm, MD PhD, Sung-Hyun Kim, MD PhD, Sukjoong Oh, MD PhD, Dae Young Zang, MD PhD, Young Rok Do, PhD MD, Won Sik Lee, MD PhD, Myung Hee Chang, MD, Sung-Eun Lee, MD PhD, Dong-Wook Kim, MD PhD

Blood (2018) 132 (Supplement 1): 3010.

https://doi.org/10.1182/blood-2018-99-117543

Published: 2018

Journal Articles

Long-Term Follow-up after Treatment Discontinuation in Patients with Chronic Myeloid Leukemia: The Korean Imatinib Discontinuation (KID) Study

Dae Young Zang, MD PhD, Won Sik Lee, MD PhD, Yeung-Chul Mun, Young Rok Do, PhD MD, Sukjoong Oh, MD PhD, Sung-Eun Lee, MD PhD, Soo Young Choi, Dong-Wook Kim, MD PhD

Blood (2018) 132 (Supplement 1): 4252.

https://doi.org/10.1182/blood-2018-99-118026

Published: 2018

Journal Articles

Comparison of Prognostic Stratification between IPI, PIT, and NCCN-IPI in the Treatment of Nodal Peripheral T-Cell Lymphomas

Ho-Young Yhim, MD PhD, Yong Park, MD, Joon Ho Moon, MD, Ho-Jin Shin, MD PhD, Yoon Seok Choi, MD, Min Kyoung Kim, MD PhD, Dae Sik Kim, MD PhD, Ji Hyun Lee, MD PhD, Won Sik Lee, MD PhD, Young Rok Do, PhDMD, Jun Soo Ham, MD, Seok Jin Kim, MD PhD, Won Seog Kim, MD PhD, Deok-Hwan Yang, MD, Jae-Yong Kwak, MD PhD

Blood (2018) 132 (Supplement 1): 1657.

https://doi.org/10.1182/blood-2018-99-115620

Published: 2018

Journal Articles

Effect on Clinical Outcomes of Anemia and Serum Level of Ferritin in Diffuse Large B Cell Lymphoma Treated with Rituximab Combined Chemotherapy

Taeyun Kim, MD, Ho Sup Lee, MD, Jee-Yeong Jeong, PhD, Jae-Cheol Jo, MD PhD, Won-Sik Lee, MD PhD, Ho-Jin Shin, MD, Ji Hyun Lee, MD PhD

Blood (2017) 130 (Supplement 1): 4158.

https://doi.org/10.1182/blood.V130.Suppl_1.4158.4158

Published: 2017

Journal Articles

Characterization of ABL Compound Mutation Using Sanger and Subcloning Sequencing in Tyrosine Kinase Inhibitor Resistant Chronic Myeloid Leukemia

Sukjoong Oh, Ki Hoon Kang, Won-Sik Lee, MD PhD, Hyeoung-Joon Kim, Jee Hyun Kong, Yunsuk Choi, MD, Young Rok Do, MD PhD, Jae-Yong Kwak, Sung-Hyun Kim, MD PhD, Jeong-A Kim, Dae Young Zang, MD PhD, Yeung-Chul Mun, MD PhD, Young-Woong Won, Sung-Eun Lee, MD, Dong-Wook Kim, MD PhD

Blood (2017) 130 (Supplement 1): 2864.

https://doi.org/10.1182/blood.V130.Suppl_1.2864.2864

Published: 2017

Journal Articles

The Impact of Early Molecular Response at 3 Months on Long-Term Survival Was Enhanced in the CP CML Patients Treated with Second-Generation Tyrosine Kinase Inhibitors

Sung-Eun Lee, MD, Won-Sik Lee, MD PhD, Hyeoung-Joon Kim, Jee Hyun Kong, Yunsuk Choi, MD, Young Rok Do, MD PhD, Jae-Yong Kwak, Sukjoong Oh, Sung-Hyun Kim, MD PhD, Jeong-A Kim, Dae Young Zang, Yeung-Chul Mun, MD PhD, Young-Woong Won, Dong-Wook Kim, MD PhD

Blood (2017) 130 (Supplement 1): 2873.

https://doi.org/10.1182/blood.V130.Suppl_1.2873.2873

Published: 2017

Journal Articles

Very Early Molecular Response at 1 Month Is a Predictor of the Outcome of Chronic Phase Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors

Won-Sik Lee, MD PhD, Hye-Young Song, Hyeoung-Joon Kim, Jee Hyun Kong, Young Rok Do, MD PhD, Jae-Yong Kwak, Sukjoong Oh, Sung-Hyun Kim, MD PhD, Jeong-A Kim, Dae Young Zang, MD PhD, Yeung-Chul Mun, MD PhD, Young-Woong Won, Sung-Eun Lee, MD, Yunsuk Choi, MD, Dong-Wook Kim, MD PhD

Blood (2017) 130 (Supplement 1): 1593.

https://doi.org/10.1182/blood.V130.Suppl_1.1593.1593

Published: 2017

Journal Articles

Predictors of General Discomfort, Limitations in Activities of Daily Living, and Intention of a Second Donation in Unrelated Hematopoietic Stem Cell Donation

Mark Lee, Jin Ho Jang, Hyo Jin Min, PhD, Hyung In Jang, Jung Hwa Nah, Chuhl Joo Lyu, MD PhD, Kyou Sup Han, MD PhD, Jong-Ho Won, MD, Young Ho Lee, MD PhD, So Young Chong, MD, Yeung Chul Mun, MD PhD, Won Sik Lee, MD PhD, Seok Jin Kim, Inho Kim, MD PhD

Blood (2016) 128 (22): 3375.

https://doi.org/10.1182/blood.V128.22.3375.3375

Published: 2016

Journal Articles

The Impact of Antithymocyte Globulin (ATG) Dose in Allogeneic Hematopoietic Stem Cell Transplantation with HLA Mismatched Donors

Yunsuk Choi, MD PhD, Ho Sup Lee, MD PhD, Je-Hwan Lee, MD, Joon Ho Moon, MD, PhD, Ho-Jin Shin, MD PhD, Won Sik Lee, MD PhD

Blood (2016) 128 (22): 3393.

https://doi.org/10.1182/blood.V128.22.3393.3393

Published: 2016

Journal Articles

Results from the Korean Imatinib Discontinuation Study (KIDS): Updated Data with 15-Month Median Follow up

Blood (2014) 124 (21): 3155.

https://doi.org/10.1182/blood.V124.21.3155.3155

Published: 2014

Journal Articles

Achieving Complete Cytogenetic Response and BCR-ABL PCR IS <1% within 12 Moths Are Important Goals for Imatinib Therapy in Newly Diagnosed, TKI-Naive Chronic Myeloid Leukemia Accelated Phase Patients

Hawk Kim, Eun-Jung Jang, Sung-Eun Lee, Won Sik Lee, MD PhD, Sukjoong Oh, MD PhD, Dong-Wook Kim, MD PhD

Blood (2014) 124 (21): 3158.

https://doi.org/10.1182/blood.V124.21.3158.3158

Published: 2014

Journal Articles

Clinical Outcomes of R-CHOP Chemotherapy Alone Compared with R-CHOP Plus Radiotherapy in Patients with Localized, Non-Bulky Diffuse Large B-Cell Lymphoma

Blood (2014) 124 (21): 4421.

https://doi.org/10.1182/blood.V124.21.4421.4421

Published: 2014

Journal Articles

Inferior Long-Term Outcome of Front-Line Hypomethylating Agent Compared to Supportive Care in Patients with Lower Risk Myelodysplastic Syndrome: Prosensity Score Matched Analysis

Sang Kyun Sohn, MD PhD, Joon Ho Moon, MD PhD, Ahn Jae Sook, MD, PhD, Hyeoung Joon Kim, MD PhD, Moo kon Song, MD, PhD, Ho-Jin Shin, MD PhD, Won Sik Lee, MD PhD, Sang Min Lee, MD PhD, Young Don Joo, MD PhD, Ho Sup Lee, Yang Soo Kim, Yoon Young Cho, MD PhD, Sung Hwa Bae

Blood (2014) 124 (21): 3255.

https://doi.org/10.1182/blood.V124.21.3255.3255

Published: 2014

NARROW

Clinical Response Evaluation Toward Individualizing the Starting Dose of Dasatinib in Asian Patients with Chronic Myeloid Leukemia

Second Imatinib Discontinuation Outcomes in Patients Regaining Durable Deep Molecular Response in the Korean Imatinib Discontinuation Study; KID Study

Current Treatment Patterns and Outcomes in Patients with Peripheral T-Cell Lymphoma: Updated Results of the Nationwide, Multi-Center Prospective Registry Study (CISL 1404)

Open-Labeled, Multicenter Phase II Study of Bortezomib for Maintenance Therapy in Patients with High Risk Diffuse Large B Cell Lymphoma (DLBCL): Borma Trial from Consortium for Improving Survival of Lymphoma (CISL)

Prognostic Significance of Interim PET/CT Assessment for the Treatment of Advanced Stage of Marginal Zone Lymphoma in the Post Immunochemotherapy Era

Results of Intercontinental Cooperative Non-Hodgkin T-Cell Lymphoma Prospective Registry Study

Long-Term Outcomes of Chronic Myeloid Leukemia Patients Who Lost Undetectable Molecular Residual Disease (UMRD) after Imatinib Discontinuation: Korean Imatinib Discontinuation Study (KIDS)

High Incidence of Hepatitis B Viral Reactivation in Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors

Long-Term Follow-up after Treatment Discontinuation in Patients with Chronic Myeloid Leukemia: The Korean Imatinib Discontinuation (KID) Study

Comparison of Prognostic Stratification between IPI, PIT, and NCCN-IPI in the Treatment of Nodal Peripheral T-Cell Lymphomas

Effect on Clinical Outcomes of Anemia and Serum Level of Ferritin in Diffuse Large B Cell Lymphoma Treated with Rituximab Combined Chemotherapy

Characterization of ABL Compound Mutation Using Sanger and Subcloning Sequencing in Tyrosine Kinase Inhibitor Resistant Chronic Myeloid Leukemia

The Impact of Early Molecular Response at 3 Months on Long-Term Survival Was Enhanced in the CP CML Patients Treated with Second-Generation Tyrosine Kinase Inhibitors

Very Early Molecular Response at 1 Month Is a Predictor of the Outcome of Chronic Phase Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors

Predictors of General Discomfort, Limitations in Activities of Daily Living, and Intention of a Second Donation in Unrelated Hematopoietic Stem Cell Donation

The Impact of Antithymocyte Globulin (ATG) Dose in Allogeneic Hematopoietic Stem Cell Transplantation with HLA Mismatched Donors

Results from the Korean Imatinib Discontinuation Study (KIDS): Updated Data with 15-Month Median Follow up

Achieving Complete Cytogenetic Response and BCR-ABL PCR IS <1% within 12 Moths Are Important Goals for Imatinib Therapy in Newly Diagnosed, TKI-Naive Chronic Myeloid Leukemia Accelated Phase Patients

Clinical Outcomes of R-CHOP Chemotherapy Alone Compared with R-CHOP Plus Radiotherapy in Patients with Localized, Non-Bulky Diffuse Large B-Cell Lymphoma

Inferior Long-Term Outcome of Front-Line Hypomethylating Agent Compared to Supportive Care in Patients with Lower Risk Myelodysplastic Syndrome: Prosensity Score Matched Analysis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only